BioSpace News Archive

XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET.

Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.

Harpoon Therapeutics, Inc. today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma.

Nautilus Biotechnology, Inc. today announced the company will be participating in the following investor conferences.

A new physician-training system in telehealth simulates key parts of traditional, in-person neurological exams that use little reflex hammers, pinpricks, and flashlights to test nerve function.

Aptose Biosciences Inc. announced closing of a $3 million investment in common shares of the Company as the first tranche of a private equity investment for up to a maximum of $7 million or 19.99 percent ownership interest by Hanmi Pharmaceutical, Inc., Seoul, South Korea.

Apnimed announced that a post-hoc analysis of data from the MARIPOSA Phase 2b trial, an efficacy, safety and dose-finding study for AD109 (aroxybutynin/atomoxetine) of one-month duration, will be featured at a poster presentation at the European Respiratory Society’s (ERS) International Congress 2023 in Milan, Italy.

MaxCyte, Inc. today announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023.

Elicio Therapeutics, Inc. today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET.